FDA Approval And BARDA Contracts Will Boost Clinical Diagnostics
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
06 May 25
Updated
24 Jul 25
AnalystConsensusTarget's Fair Value
US$5.09
52.8% undervalued intrinsic discount24 Jul
US$2.40
1Y
64.9%7D
-3.2%